Adaptimmune Therapeutics PLC - ADR (ADAP) is near the top in its industry group according to InvestorsObserver. ADAP gets an overall rating of 83. That means it scores higher than 83 percent of stocks. Adaptimmune Therapeutics PLC - ADR gets a 96 rank in the Biotechnology industry. Biotechnology is number 18 out of 148 industries.
ADAP has an Overall Score of 83. Find out what this means to you and get the rest of the rankings on ADAP!
Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. InvestorsObserver makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.
This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.
What's Happening With Adaptimmune Therapeutics PLC - ADR Stock Today?
Adaptimmune Therapeutics PLC - ADR (ADAP) stock is lower by -0.97% while the S&P 500 is higher by 0.82% as of 1:22 PM on Tuesday, Mar 12. ADAP has fallen -$0.01 from the previous closing price of $1.54 on volume of 1,369,693 shares. Over the past year the S&P 500 has gained 33.83% while ADAP is higher by 37.84%. ADAP lost -$0.57 per share the over the last 12 months.
Click Here to get the full Stock Report for Adaptimmune Therapeutics PLC - ADR stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
